Observational analysis revealed that NRAS and KRAS mutations influence long-term outcomes in acute myeloid leukemia patients post transplant, indicating new risk stratification potential.
Key Points
Long-term outcomes were positively influenced by NRAS and KRAS mutations, with over 60% remaining leukemia-free after 2 years.
Acute myeloid leukemia patients showed varying post-transplant survival rates depending on their mutation status and cytogenetic risk.
Observational analysis across multiple centers analyzed data from patients with NRAS and KRAS mutations undergoing allo-HCT.
Findings point to the need for transplant-specific risk stratification to predict long-term outcomes in this patient group.